ashlee: space pharma wants to use these machines to see what space can teach us.ll myself out of the clouds and learn more about israel's startup culture, i went for a walk on the beach back in tel aviv with another local tech legend. [laughter] adi: hello. welcome to israel. ashlee: thank you very much. armed with a law degree, and an mba, adi soffer-teeni has led a number of young companies and helped spur on israel's technology culture. now, she runs facebook's israel operations. adi: today we have something like 5300 startups in israel. by the way, there is no one country in a world that has that amount of start up success except for the u.s. ok? 1400 startups in 2015. 1400 new startups. ♪ ashlee: women must serve alongside men in the military here. adi once hoped to fly jets, but because of the gender restrictions at the time, she ended up evaluating who could become a pilot. she sees the time in the air force as crucial to her career. what is the uniqueness of the female experience in israel because of the military service? it must have some long-term effect

when you look at big pharma, there are few industries as reshaped by big pharma as m&a and m&a has displacedre in the. many times from an economic standpoint, it is cheaper to buy with a newompany drug than to spend the time. j&j and pfizer are active in buying companies. given the status of obamacare, does that impact to m&a? or is now the time to be aggressive, even though they don't know what the government plan is? >> you have to deconstruct the health care industry. obamacare and its repeal affected certain segments of it. it is going to have far more of an effect on them than compared to big pharma, looking to continue to build out the pipeline and acquire companies. it will have less of an effect on that part of the industry. health i.t. at players will be less affected. >> paul is going to stay with us. we will talk about donald trump next. vonnie: excellent. looking forward to that. we will be talking about apple and its suppliers. imagination technologies having their worst day after apple said ties with the company. this is bloomberg. ♪ vonnie: this is bloomberg markets. i am vonn

and tourette's syndrome, i'm invested in a few of the companies. >> this is a speculative one, gw pharmationwide is going to hurt both companies, that is the end of the lightning round. >> t h the dog-sized horse? i'm crazy stressed trying to figure out this complex trade so i brought in my comfort pony, warren, to help me deal. isn't that right warren? well, you could get support from thinkorswim's in-app chat. it lets you chat and share your screen directly with a live person right from the app, so you don't need a comfort pony. oh, so what about my motivational meerkat? in-app chat on thinkorswim. only at td ameritrade. >>> does it matter if this british election occurs with a snap? do we need to be worried about the german elections come the fall? if you're a hedge fund manager, absolutely you do need to worry. if you're a bond fund manager, definitely. fund managers have to worry about short-term gains. but if you're an individual investor, it's a different story, you can be aware of european moll ticks, but i hesitate to do more than that, because i'm afraid you'll take action. and

we have been a little slower to do this on the pharma side. i do not know if it is lobbying, but given the antagonism towards this industry, it seems to me we have an opportunity to say we will reward you if you develop drugs that work and we only want you to use them on the patients for whom they are indicated and you are not going to be reimbursed for pushing your pills on off label uses where there is no evidence of effectiveness unless you can show it works. it seems to me it is the right time for that type of grand bar. -- grand bargain. moderator: can you talk about off labeling? that was something interesting for me when i saw your film. i did not realize that. >> i really want to say one thing about what you said, because i think it is very important in terms of rewarding doctors for better outcomes. the administrative burden put on doctors offices and private practices is cost prohibitive to do some of those. that is one problem. as far as off labeling, off labeling is when you have a medication that has been fda-approved for some rea

finally look at the daily chart of another company, kite pharma.he immunotherapy plays that's been all over the map. kite's stock roared 50% higher in just three days, nice. since then it's been trading sideways. he thinks it's important to note that once again we have got a stock that's building a base at a higher level. he loves that. lang says you're getting a low risk entry point and that floor of support has already been tested and held twice, boom, boom. if kite can break above $85, which is a few bucks above here, $7, lang believes it's a straight shot to $100. here's the bottom line, sometimes political worries are simply a smoke screen to scare you out of high quality stock. i think it's a political red herring, and the charts charts. we have a food fight heating up in the market, is there enough room in the market for whole foods and it's new organic and natural competitors. and the worldwide market for spinal surgical robots are expected to move over 2 billion by 2022. with rumblings of more big deals to come. could there be an unintende

and just about every big pharma is here, hawking products. so let‘s seem here, hawking products.d have a look. how much is this cost? the cost of a helicopter in the basic version, it should be around, all included, about10.4 should be around, all included, about 10.4 million euros in 2017. that is a lot of money. so who buys these things? vips, of cores. we also have oil and gas operators. —— offcourse. doctors also have oil and gas operators. —— offcou rse. doctors love also have oil and gas operators. —— offcourse. doctors love the interior and it can be used as a long—range ambulance. finally, it is public services, which might include search and rescue missions, and others who need this size of a helicopter. —— of course. let's find out who some of course. let's find out who some of these buyers are. this man has his place in orderfor three helicopters, amounting to $60 million. he is with an aircraft maintenance and charter firm. time is money. we make deals happen. people who come into the country or arrived in manila, we fly them to their meeting place, to our helipad. th

pharma and biotech are the real spaces that health care investors will like right now.ap biotech really isn't so great t. reason they like pharma is the potential for tax reform and for sector consolidation or mna. in terms of which names might be potential buyers and targets. looking at pfizer, merck, gilead and cellgene, on the target side, companies as big as alexion and inside and genetics and tesaro. we seen tesaro stock down as they put out plans to launch their new cancer drug. people take that to mean maybe they won't be a potential target. biotech earnings check in week. they are saying it could be a mixed bag in terms of performance, of folks who could beat, looking at potentially alexion, cellgene where they think amgen comes in. on the positive side. you haven't seen negative pre announcements, for these companies, meaning it could go well. there is seasonal weakness. on the positive sidesh that means from an investment standpoint, drug price increases are still happening, even amid this, 40 in this year versus 23 in 2016. they seem like they're accelerating

said her, desk sector, don't like telecommunications -- sector, don't like telecommunications, like pharmamoney -- jonathan: do you see the same sector breakdown? martin: looking at the overall picture, we compare the spread on emerging markets, high-yield and u.s. high-yield, and then do some further processing on that to adjust for the difference in ratings mix in those two indexes. and emerging-market, even after that adjustment, is always wider now the u.s.. the question is how much? andt now, not enough emerging markets are very expensive relative to u.s. high-yield. jonathan: do you agree, fran? fran: what proxy are you using? high-yield credit? martin: yes. fran: i wanted to highlight with an emerging market, people talk about going to em debt. they could be talking about dollar sovereign, dollar corporate, or local currency sovereign. within the corporate sector, emerging-market high-yield is "higher-quality" than the u.s., and it is harder for many emerging market issue ways to earn that rating. the fact that you get that in a spread in the u.s. high-yield over a shorter duration,

subsector specific we would like the banking sector, we don't like telik mitigation's, we don't like pharmawe like energy. our head of investment grade credit likes to say, lend money to someone who does not need it, don't lend money to someone who does not need it. jonathan: a great slogan. do you see the breakdown at the moment? >> looking at the overall picture, we compare spreads on emerging markets, high yield, and u.s. high-yield, introducing further processing on that to adjust for the difference in ratings mix in those two indexes. emerging markets even after that adjustment, it is always wider than the u.s. and the question .s how much wider right now, not enough. >> what proxy are you using for emerging markets? high-yield credit? >> yes. >> yes. i want to highlight within emerging markets, people talking about going into debt, talking about dollar sovereigns, dollar court friends -- within the credit sector alone, credit sector high yields, is higher quality than the u.s. it is harder for many emerging market issuers to earn the rating. the fact that you get that and the spread o

they will target bigger pharma. >> the bigger pharma stocks i would imagine, the potential are eitherriced in or they're such a small drop in the bucket it doesn't necessarily move the needle for them. >> yeah, people have been decharting these drugs, so their potential approval is pretty well expected. then the upside comes through the smaller companies, and potential mna. >> most interesting one on that list, eli lilly had a monster move. it's getting rich, tesaro mentioned that's been the speculation on that stock the last couple of years. i've we heard anywhere from $210 to $225. it's had a massive move off negative news. i think the risk reward, which is substantial, is 1 twiefr on the downside and a special to get a takeout anywhere from 210 to 255. >> incyte, i like, they have late stage pipeline that absolutely is incredible with block busters here and there and everywhere. that's a really impressive one that will be taken out sought soat some point, i don't know when. >> we talk gilead all the time. >> that will be the savior if they make that move. >> bio tech had a nice per

we should not be pandering and catering to audiences like big pharma. we should not be catering to insurance companies. [applause] thatan american and i know we use the word patriotism and patriots a lot. i think we could agree that they are all great americans. he defined patriotism by saying it does not mean stand by the president or any other political by which he himself stands by the come -- country. it is patriotic to officially serve the country. it is unpatriotic to oppose him to the exact extent by inefficiency or otherwise he fails in his duty to stand by the country. in either event, it is unpatriotic to not tell the truth whether about the president or anyone else, but to tell the truth about health care, let's talk about what americans need and let's protect the constituents and not the big entrance pharma. thank you. [applause] rep. barton: that shows we are running a fair townhall, because her number got pulled in mansfield and it got pulled again today. >> [inaudible] rep. barton: well a number was pulled that you used however you got to

we don't like pharma. we don't like energy.ead of credit says lend someone who doesn't need it. jonathan: do you see the same fame at the moment? martin: we compare the spreads on emerging markets, high-yield, and u.s. high-yield and then do some further processing on that to adjust for the difference in ratings makes and those two indexes -- ratings makes in those two indexes, and it's always whiter than the u.s., but the question is how much wider? right now, not enough and the emerging markets are relatively expensive. jonathan: do you agree with that, fran? fran: what proxy are using for emerging markets? are you looking at high-yield credits? martin: yes. fran: i wanted to highlight within emerging markets that people are talking about going to em debt and they should be talking about dollars sovereign's, dollar corporate's, or local currency sovereigns. within the credit sector alone, emerging market high-yield is "higher-quality" than the u.s. it's a low to mid double be on average and it's hard for many emerging market

. >> tucker: happened to purdue pharma? that they make good money on a?ackler family, they are number 16 on the list of the forbes richest families. >> tucker: just for selling oxycontin? >> the lion share of their businesses of purdue pharma business is in oxycontin. >> tucker: 30 seconds left, if you could do one thing to stop this, not to treat the people currently addicted, but to become people more addicted, what it would be? >> i think there is a big problem with fentanyl, which is an artificial opioids that can be made from a lab coming in from china and mexico. i think that things can be done to interdict it. >> tucker: and that is the deadliest of all the opioids and derivatives? >> it's about 50 times as strong as normal heroin. and dealers like to cut it by a factor of 50 so it's normal. but they don't always do a good job, and so is highly unpredictable. and it leads to a lot of overdoses.s. >> tucker: christopher caldwell, the piece is "american carnage." it's on our facebook page. thank you for joining us. >> thank you. >> tucker: up next, t

we should be talking about taking care of citizens and not catering to big pharma. we should not be catering to insurance companies. i am an american. i know that we hear the word patriotism and patriot thrown round. roosevelt defined it as standing by the country. not standing by the president or any other political official saying to the degree he helms stands by the country. it is patriotic to support him so far as he sufficiently serves the country. it is unpatriotic to support him to the -- he fails in his duty to stand by the country. in either event, it is unpatriotic not to tell the truth whether about the president or anyone else, but to tell the truth about healthcare, let's talk about what americans need and let's protect the constituents and not the big interest pharma. [applause] rep. barton: that shows that we are running a fair town hall. her number got pulled again in mansfield and again today. a number was pulled that you used. however you got to use it. my answer is going to be about the same as it was two or three days ago. the affordable care abo

but as for what big pharma does, it provides us with life-saving drugs. if you're not getting the right kind, hopefully that is a problem that can get fixed with something like single-payer. one of the great things about america is people here do not accept second rate. that is one reason i think single-payer would work. host: the way back, restoring the promise of america, what is that book about? guest: the book is about what i thought was the key to the trump campaign. andid -- i sent trump advanced copy. he communicated that he liked it a great deal. he plugged my book which proves heher it is better than thinks or he did not read the book. i say there is one key problem -- people are finding that their kids are doing worse than they did. that is crucial. that is what is behind everything in the trump agenda. behind immigration plans, his attack on crony capitalism, about his k-12 plans. geared to making us more mobile. that is the american dream, and the problem is the american dream has fled to other countries. health care fits in in the sense that

we should be talking about care for citizens and not pandering and tailoring to lobbying big pharma. we should not be tailoring to insurance companies. [applause] i am an american and i know that we hear the word patriotism and patriots a lot thrown around. teddy roosevelt was a great american. i think we could probably all agree on that. he defined patriots and by saint patriotism means standing by your country but it does that mean -- [inaudible] to the degree to which himself he himself stands by the country. it is patriotic as he officially serves the country. it is unpatriotic to oppose him to the exact extent that by inefficiency or otherwise he fails and is a duty to stand by the country. in either event it is unpatriotic not to tell the truth, whether about the president or anyone else. but to tell the truth about healthcare, let's talk about what americans need and let's protect the constituents and not that big interest pharma. thank you. [applause] >> well, that shows where running a fair townhall, because her number coupled in mansfield and a couple again today. [inaudibl

big pharma. we should not be catering to insurance monies, i am american. and i know that we have to work in a patriots a lot in the program. they are really great americans, i think we probably all agree on that. he defined patriotism by saying patriotism does not mean standing by any other public official saying a degree in which he himself stands by the country. it is patriotic for him as he efficiently serves the country. >> is unpatriotic to oppose him to the exact extent that inefficiency or otherwise he felt his duty to stand by the country. >> in either event, it is unpatriotic not to tell the truth, whether about the president or anyone else but tell the truth about healthcare. let's talk about what americans need and let's affect the constituents and not the interest pharma. thank you. >>. >> that shows we are running a fair town hall because i never got cold in mansfield and he got cold again today. >>. >> and member was pulled and you used it, however you got to use it. my answer is going to be about the same as it was two or three days ago. the

we don't allow foreign competition, do allow healthcare providers to consolidate, from ever-bigger pharma to ever- bigger hospitals. >> in the 80nd 90's is, there was consolidation of hospitals. and a lot of those in the early phases were about efficiency. but at a certain point, consolidation in local markets becomes effectively monopoly. >> reporter: and, this is the classic dilemma of mergers and acquisitions, right? >> exactly. >> reporter: you merge or acquire another company because you will then have market power to buy things in bulk and therefore more cheaply and you won't be repeating the things that you each individually were doing. >> right. >> reporter: but then, if there are no competitors left, you can charge whatever you want. >> right. and we have reached the level of consolidation in many markets in healthcare where there isn't effectively competition. >> reporter: and as providers consolidate, so do payers. there are now just five mega health insurers, and only that many because judges just blocked anthem's $48 billion deal to buy cigna, aetna's $37 billion bid for huma

we like the banking sector, don't like telecommunications, don't like pharma, we like energy.ead of investment grade credits likes to say, lend money to someone who doesn't need it, don't lend money to someone who needs it. jonathan: do you see the same sector breakdown at the moment? martin: looking at the overall picture, we compare the spreads on emerging markets, high-yield, and u.s. high-yield, and then do some further processing on that to adjust for the difference in ratings mix in those two indexes. and emerging-marke, even after that adjustment, is always wider than the u.s. the question is how much wider? right now, not enough and emerging markets are very expensive relative to u.s. high-yield. jonathan: do you agree, fran? fran: i want to ask marty, what proxy are you using for emerging markets? high-yield credit within emerging market or? martin: yes. fran: i wanted to highlight within emerging markets, people talk about going to em debt. they could be talking about dollar sovereigns, dollar corporates, or local currency sovereigns. within the credit sector, emergi

how big pharma is using research from iceland to uncover cures. >>> now an update on that ongoing story involving united airlines. ceo oscar munoz speaking out about this clip seen around the world, showing a united flier, dr. david dow, being dragged off a plane. munoz said he was ashamed and promised united would never again use police force to remove paid passengers on overfilled flights. munoz came under fire for his initial reaction to the incident and he took the opportunity to clarif >> my first reaction to most issues is to get the facts and circumstances. and the initial -- my initial words fell short of truly expressing what we were feeling. and that's something that i've learned from, the expression of apology and specific to the folks i mentioned before is an important part of a conversation like this, because again, that shame and embarrassment was pretty palpable for me and for a lot of our family. >> munoz also said he would not resign despite the explosive backlash that has ensued following the video's release. on top of that united announcing all passengers on that flig

pharma. >> iceland is known for pockets of geothermal activity and lava fields and volcanos and dramatic waterfalls. less well-known are its contributions to medical research, coming up. >>> an update on the pr debacle at united airlines. shares of the company took a hit in today's session. this video footage shows a man being dragged down the aisle of his flight by security because he refused to give up his seat. originally the airline said the flight was overbooked but since has backtracked, saying the flight was not technically overbooked. united said it needed the passenger's seat to accommodate crew members who needed to be in louisville the next day for their flights. uni united's ceo oscar munoz has issued a few apologies. at first he said the passenger was disruptive and belligerent. later he issued another statement saying no one should be mistreated this way. the incident has led many consumers to wonder what their rights are. what does owning an airline ticket really mean? how often are passengers, quote, reaccommodated, to use oscar munoz's soothing term? >> reporter: draggin

. >> we grew 9% for the pharma business, and more than all of it was attributed to the new products. it was a solid operating quarter for the company. >> eli lily shares fell to $81.20. >>> ibm raised its guidance. it signed with abb to create and develop new industrial products. ibm shares fell 36 cents to $160.39. >>> rite aid says the ongoing merger process with walgreen's negatively impacted its quarterly. still, it managed to top earnings and estimates and says it's working with the federal trade commission to wrap up its merger with walgreen's by mid-summer. shares of rite aid popped 6% to $3.97. >>> lockheed martin posted a rise in sales but missed estimates due to charges that the company booked related to its foreign contracts. but it did raise its revenue forecast for the year. as for profit, the company beat expectations but said it was lowering its outlook for 2017. the shares were off 2% to $270.02. >>> the mining company freeport turned a profit and recorded higher sales, but results fell short of estimates. the company said it will resume operations at its indonesia li

within health care, biotechnology stocks, continued stocks for the big pharma companies. >> thank you, mark, as always. >> thank you for having me. >>> softer economic data, we start with manufacturing activity in the new york region which grew at a slower pace than april. orders were not as strong as they had been, despite six straight months of expansion. and hiring remains strong. and new york area manufacturers are still optimistic about future conditions. home builder sentiment also cooled. the national association of home builders survey shows the industry is optimistic heading into the spring selling season. the group is also confident that the president's promise of looser regulation and faster growth will offset challenges like higher costs. >>> as we've been reporting, there is a divide in the economic data. some of the so-called softer data like sentiment is very strong. while other harder data like retail sales is weak. and usual rily when consumer confidence rising is sensitive. steve liesman has more. >> an exuberant consumer is your best customer, at least what the conv

carol: also, i looked at big pharma monitoring gadgets that want to know everything about your body.tory is about one of the holdings under the alphabet holding company. it was fun out by itself. carol: tell us what this study is about and who is involved. >> the baseline study refers to setting a starting point, and they have recruited 10,000 healthy participants because they are trying to answer the question of what does healthy look like. so they will gather all sorts of data from dna, bacteria, a psychological assessment, and they will run them through various tests, cardio tests, stress tests, and have them come back over four years so they can start to see what do healthy people actually look like while logically, then if there are people who have a family history of certain types of cancer or cardiovascular disease, they will be watching those people to see if they turn into having a disease, and how does that change, so they are asking super fundamental questions, but it is a huge study. carol: you also point out that some will be sharing data from insurance claims, health re

is the president and founder of the raleigh group of and finally the former president and ceo of pharma and ed member. thank you for joining us and being here. what an issue. take it away. fax thank you very much. we are stepping backwards. we just talked about tax reform which is next on the agenda and now we are going back words to health care which i was at an event the other night and they how it failedout and i think a more up to. term is that it is on positive. i will start with a couple of facts and figures and things that i think are interesting about the health care market and affordable care act stop then i think we will jump into the discussion. when the affordable care act was passed, there were projections about how it would affect enrollment. 42017, where were we supposed to be? the projection was we would have 25 million enrollees through the affordable care act. there are 12.2 million and it seems like it has flatlined. it is not growing anymore. when there is a commentary that there is a failed piece of health plansthe continue to exist in markets. havef regions will on

let's talk about what americans need and let's check the constituents and not the big interest pharma. thank you. >> we are running a beer town hall because her number got pulled and mansfield and it got pulled here today. a number was pulled and however you got to use it. my answer is going to be the same as it was two or three days ago. the affordable care act isn't working. it's not working. if hillary clinton had one we would be trying to fix fix it f. we are just trying to fix fix in a little different way. your coverage under pre-existing conditions under the affordable care at, you will be covered under a repeal and replace bill. pre-existing conditions are going to be covered. pre-existing conditions will be covered. how you do it, it's my turn to talk. i listen to you. you can listen to me. no matter -- you are concerned about having coverage for your drug prescription and you are concerned that you are going to have health insurance. it's going to happen. if a state chooses to use the high-risk pool and they put you in that you probably won't even know it. the only way, the

companies have pulled out including major automakers and pharma companies. >>> meantime, the u.s. ordered an aircraft carrier group closer to the korean peninsula. the carrier group called "u.s.s. carl vinson" was instructed to travel north on saturday. the u.s. military described it as a show. trump aides offered few details on how the two countries intend stod work together in the future. let's get out to cnbc sophia yao in beijing. it's what is the response from the chinese media, obviously, they have to response, too? >> absolutely. chinese state media has been quite positive, covering this whole meeting between u.s. president donald trump and chinese president xi jinping is a constructive meeting, one that is friendly in tone. it went so well, actually in reality, that the two parties were able to come to an agreement to try to meet in the middle. there's a 100-day plan to try to tackle the bilateral adjustment between the two countries that the u.s. in particular that china will try to give u.s. better access on that's financial sector experts and beef exports. now analysts

and vertex pharma has been trying to develop a strong cystic fibrosis franchise, as has seemed to have unlocked the code to this particular disease. this one traded in the 140s back when the market first thought it developed something good for cystic fibrosis before a set back. that's why i think this stock has room to run. oddly, arconic gave its name to the spinoff, choosspinoff,. arconic -- with elliott management trying to unseat the ceo clarence klein feld, and replace him with larry lawson, we own arconic in my travel trust, and it wouldn't -- that makes the stock a little fraud at these levels. even if it's down 4 bucks from its high. it's too cheap on the possibility of a takeover, which i know the elliott guys would like to try something like that. but it's too expensive on earnings. first quarter's fourth best performer? this one's a lot easier, it's active vision blizzard. the game developer. we like to talk about big themes on this show, and video game makers like activation blizzard, they uniquely fit into the stay at home and entertain yourself thesis that has made a ton

southwestern energy, vertex pharma also. and take a look at tesla marching higher once again.pain in shortville. stock trading above 300 bucks for the first time ever. >>> meantime, president trump hosting ceos at the white house today and sounding very pro-business saying he will cut regulation more and spend a trillion dollars on infrastructure. our own eamon javers was there and joins us now from the white house with some of the highlights. >> reporter: what a session. dozens of ceos and top executives at the white house to meet with the president, his daughter ivanka trump, the vice president and a whole host of administration officials here. they did a couple breakout sessions, roundtable discussions on a number of issues. at one point the president said we're going to do things that are very good for the banks and he talked about his dodd/frank rollback plans. here's what he said. >> you look at the folks from government that are running all over the banks. they're running the banks. the people that are really, you know, the head people, they're petrified of regulators.

in the pharma says, bayer reporting sales ahead of forecast and raising full-year guidance.hares up about 3.5%. >> nokia beating analysts forecast expecting sales of the network unit to decline this year in line with the market. up 6%. >>> amgen's quarterly profit topping expectations offsetting a sharp drop in sales of a blockbuster drop. the company reporting a double digit sales deline fcline for a rheumatoid arthritis drug. >>> and airbus hurt by weak pricing and higher costs. airbus facing an issue with a key engine supplier. >>> still ahead, remember this bbc interview that went completely viral? the internet's favorite interrupting kids are back that story when we return. thanks for loading, sweetie. ...oh, burnt-on gravy? ...gotta rinse that. nope. no way. nada. really? dish issues? throw it all in. new cascade platinum powers through... even burnt-on gravy. nice. cascade. >>> welcome back to "worldwide exchange." time for our top trending stories. the bbc interview kids are back. the two children who famously crashed their father's bbc interview are getting their ow

finally john cass tee lanni former president of pharma and cdc member. thank you all for joining us and being here and, boy, what an issue. sean, take it away. >> thank you very much. so i feel like we're stepping backwards. we talked about tax reform which is next on the agenda and now we're going backwards to health care which is -- i was at an event the other night and they're talking about it's failed and i think the more appropriate term was it's paused and it seems like it'll be taking up again. i'll just start with a couple facts and figures and things that i think are interesting about the health care market, the affordable care act and i think we'll jump into the discussion. when the affordable care act was passed there's some projections as to how that would effect enrollment. for 2017 where are we supposed to be? the projection was that we would have 25 million enrollees through the affordable care act. as of february there are 12.2 million and it seems like it's also flat lined. it's not growing any more. so when there is a commentary that it

sharp increase in prescribing which was a result in a multifaceted campaign underwritten largely by pharmahe major of oxycontin. what that campaign it did was it to minimize the risk of opioids like the risk of addiction and exaggerated the benefits of using opioids long term. the medical community began to hear that we had been allowing patients to suffer needlessly because of an fear of addiction, that's a compassionate way to treat just about any complaint of pain. it led to a public health catastrophe print >> tucker: i've noticed it just seems like a legal drug dealing to me. thanks a lot for coming on tonight. up next, students at one university say they don't want to want to check fillet on because it would make them feel unsafe. because they're going to starve to death when it closes on sunday? sunday? could there be the following ad is being condensed for your viewing convenience. i finally switched to geico. oh yeah? ended up saving a ton of money on car insurance. i hear they have a really great mobile app. the interface is remarkably intuitive. that's so important. ♪ >> there a

the wall is a very how much of it is drug dealers from mexico or wherever and how much of is big pharmang opiods in a way that's irresponsible? >> i think it's both. jake, i think there's no doubt that the cheap pure heroin that is coming up from over our southern border it is replacing opiods. the dynamic is this for people who really studied it and we have in new jersey. 4 out of five heroin addicts start with addictive opiods. they get addicted almost immediately. people have addictive personality or addictive disorder, they get they're too expensive. the problem that the president's talking about is the cheap, pure heroin that's coming up that's so much cheaper than the opioids that people immediately become heroin addicts with all the criminal aspects that attach to that, with the infectious aspects that come to that and the death. in new jersey last year, four times the number of people who were murdered by a gun died of opioid overdose. >> that's insane. >> three times the number of people that died in automobile accident died in opioid. three-times of the number of people that d

sharp increase in prescribing which was a result in a multifaceted campaign underwritten largely by pharmaoxycontin. what that campaign it did was it to minimize the risk of opioids like the risk of addiction and exaggerated the benefits of using opioids long term. the medical community began to hear that we had been allowing patients to suffer needlessly because of an fear of addiction, that's a compassionate way to treat just about any complaint of pain. it led to a public health catastrophe print >> tucker: i've noticed it just seems like a legal drug dealing to me. thanks a lot for coming on tonight. up next, students at one university say they don't want to want to check fillet on because it would make them feel unsafe. because they're going to starve to death when it closes on sunday? could there be another reason, our panel next we've done well in life, with help from our advisor, we made it through many market swings. sure we could travel, take it easy... but we've never been the type to just sit back... not when we've got so much more to give when you have the right financial advi

how much of it is drug dealers from mexico or from wherever and how much of it is big pharma pushingway that's irresponsible? >> well, i think it's a bit of both, jake. i think there's no doubt that the cheap, pure heroin that is coming up from over our southern border is replacing opioids. the dynamic for this for people that really studied it. four out of every five heroin addicts the start on prescription opioids. >> they get a prescription from the doctor, they're in some sort of pain. >> and they get addicted almost immediately. people who have an addictive personality or disorder, they get addicted almost immediately, but then they can't get the opioid. they're too expensive. the problem that the president's talking about is the cheap, pure heroin that's coming up that's so much cheaper than the opioids that people immediately become heroin addicts with all the criminal aspects that attach to that, with the infectious asp t aspects that come to that and the death. in new jersey last year, four times the number of people who were murdered by a gun died of opioid overdose. >> tha

ballots, -- show balance, i think too many strategists made their way onto television and were given pharma credibility -- given far more credibility than they deserved. i saw someone on television say republican or democratic strategist. what does that mean? they put out yard signs in the previous campaign? didn't take long to listen to the to understand they had no understanding and no contact with either of the candidates, but there they were. i think for whatever reason, perhaps to add drama to increase rates, we tended to make too much of slight changes in the polls. we talked about one candidate or another leading by a single point, when in fact the shifts in those polls were well within the margin of error. there is no such thing as a one-point lead in any poll. i think we also placed too much faith in general in polling. the truth is, pulling is simply not as good as it once was, where respondents were once honored to be a part of polls. now people want nothing to do with pollsters. -- artan, fewer than 10% of people polled now are willing to actually talk to a pollster on the phone

where america leads in the world, our creativity, our innovation from the high-tech field, from the pharma few. we need to make sure when americans create things, that their intellectual property is preserved a he this he get credited financially and otherwise for those creations that are uniquely american and to have them stole in china without the ability of those protections is a major trade issue. there are many major economic issues at stake in addition to the security questions between these two leaders. >> thanks, senator menendez, for joining us. we're going to continue our special coverage. you see the chinese president, the secretary of state of the united states and their wives. they are posing now for photos. our special coverage continues right now right here on cnn. >>> all right. you are watching cnn. we have just even the leader of china, president xi, his wife, other dig nataries just deplane before they are swept off to president trump's club, mar-a-lago, where they will be holding talks, incredibly important conversations over the course of the next couple of days. i'm s

that's the populist campaign, that's back to that pharma companies, that's an easy one. it can speak to the people, talking about lower drug price, it's fought pro business or business friendly, but it is speaking to the people. to me xlv, i probably sound like a broken record, it's been pinned at 74 for two weeks now. i think you see 70 in the next few weeks. this is one despite the valuations they will come back to. >> i think you are right. the things i would go back to are global markets and nick was talking about, what's refreshing of nick's view, it's almost devoid, basically saying, let's get back to where we were. look at the confidence numbers out of germany, basically, zew index near the highs. the stories out of there. i added germany, some spain. i'm doing that to names like telephonetica, big players cheap in this economy. >> watch you on tv, you are on all day long. what was interesting to me the fact that on a benign tape at the end of the day, russ emwas up almost .8 of the day. that's the good news, bad news and financials, gold man sax has not been able

sharp increase in prescribing which was a result in a multifaceted campaign underwritten largely by pharmahe major of oxycontin. that campaign it did was it minimize the risk of opioids like the risk of addiction and exaggerated the benefits of using opioids long term. the medical community began to hear that we had been allowing patients to suffer needlessly because of an fear of addiction, that's a compassionate way to treat just about any complaint of pain. it led to a public health catastrophe. >> tucker: i've noticed it just seems like a legal drug dealing to me. thanks a lot for coming on tonight. up next, students at one university say they don't want chikfila on their campus because it would make them feel unsafe. they're going to starve to death when it closes on sunday? could there be another reason, our panel next all of our property that was damaged. and we didn't have to touch our savings. yeah, our insurance won't do that. well, there goes my boat. you can leave worry behind when liberty stands with you™. liberty stands with you™ liberty mutual insurance we're out ink,nk! not

bill because it was basically just a different set of giveaways to the insurance companies and to pharma. and the freedom caucus guys hated it because it didn't look bold enough. it was too gutless. and the rest of the republican caucus hated it because it looked too heartless. the thing was a hot mess from the get-go. but trump was trying to sell what trump always sells, which is sort of a flatulent mass of his own fantasy about what the product. so he got out there. he talked fast. he said things like oh, don't pay attention to the details. we're just going to do something great together. well, this guy is entirely contingent, he is entirely impulsive. at the end of the day, the voters weren't buying it. and the members of congress on the republican said no, we're not going to set ourselves on fire for a bad bill that has bad outcomes both politically and policy wise for this guy who is a snake who will turn and bite us on the ass in a hot second, which he did. >> memo to donald trump, the freedom caucus is the tea party. they specialize in going after other republicans. they're not af